experience suggest that CREON is effective and safe in patients with EPI regardless of etiology, with a very favorable risk-benefit profile.
For exogenous PERT to be effective, it is crucial that as much as possible of the dose reaches the proximal small intestine at the same time as the partially digested food (chyme).
Lipase is the most sensitive of the pancreatic enzymes to the effects of both pepsin and acid, and is irreversibly inactivated at pH 4.0 or lower. 7 Early PERT preparations consisting of tablets or encapsulated powder were not protected against such inactivation in the stomach, and perhaps only as little as 8% of ingested lipase was bioavailable in the small intestine. Therefore, it was necessary to administer orally up to five to 10 times as much lipase as was required should be provided as soon as EPI is confirmed, whatever the patient's age and mode of feeding, in order to maintain normal growth status.
Current Recommendations and Practice for the Treatment of Exocrine Pancreatic

Insufficiency in Cystic Fibrosis
The standard of care for EPI is based on oral PERT, regardless of etiology. The dosing guidelines for patients with CF are summarized in Table 1 . [21] [22] [23] [24] [25] The occurrence in the 1990s of fibrosing colonopathy (FC) in young children receiving very high daily doses of PERT 40,41 had a major impact on PERT prescriptions, despite the rarity of this severe gastrointestinal complication. 
Efficacy of CREON in Cystic Fibrosis
The efficacy The data summarized in Table 3 Significant improvements in these parameters versus placebo were seen with CREON in both 
Safety of CREON in Cystic Fibrosis
The long-term safety profile of PERT, such as CREON, has been described in the medical literature, with the most commonly reported adverse events being gastrointestinal disorders and allergic skin reactions (rash, urticaria).
20 Table 4 with schedule C (all P<0.0001 versus baseline value of 24%) using the 13 C-mixed triglyceride breath test. There was no difference in patients' preference for the three dosing schedules in this study. Fat digestion was optimal when the enzyme preparations were taken during or after meals, and tended to be better than that observed when capsules were administered just before meals although the differences were not significant; therefore, these results should not be used as a recommendation for CREON dosing.
The US prescribing information for CREON recommends administration during meals in all patients with EPI; 20 however, in practice,
PERT is often administered before meals as well as during meals in patients with CF, whereas in non-CF patients it is often administered after meals.
In a randomized, double-blind, multicenter, 
POTENTIAL RISKS OF PANCREATIC ENZYME REPLACEMENT THERAPY
Fibrosing Colonopathy
FC is a painful condition characterized by shortening and fibrosis of the colon, 79 and is a recognized gastrointestinal complication seen almost exclusively in patients with CF. PERT products, the manufacturer of CREON will conduct a 10-year observational study looking at the incidence of and risk factors associated with FC in patients with CF in the USA (this is a class requirement for all PERT manufacturers).
Potential for Viral Transmission
The active ingredient of CREON, pancrelipase, is a mixture of digestive enzymes extracted from porcine pancreas glands harvested from pigs raised and slaughtered for food production.
However, as with all porcine-derived PERT products, the possibility of contamination of the starting material with swine viruses capable of infecting humans has to be considered. 
